Vertex Pharmaceuticals Incorporated
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | $646.3M | $913.0M | $1.05B |
| Depreciation & Amortization | $56.5M | $55.9M | $55.7M | $54.0M | $51.7M | $48.4M | $46.5M | $53.2M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $170.2M | $166.4M | $157.6M | $194.9M | $167.3M | $166.1M | $167.8M | $184.6M |
| Net Cash from Operating Activities | $1.13B | $1.43B | $498.0M | $1.24B | $1.07B | $818.9M | $584.6M | $1.37B |
| Investing Activities | ||||||||
| Capital Expenditures | $112.2M | $133.4M | $149.4M | $101.8M | $145.7M | $40.7M | $92.6M | $67.7M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-45.8M | $-431.9M | $-288.1M | $-117.0M | $-484.5M | $-55.8M | $-821.9M | $-348.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $469.5M | $336.9M | $128.4M | $1.07B | $391.8M | $426.1M | $417.9M | $307.7M |
| Net Cash from Financing Activities | $-426.7M | $-538.8M | $-77.2M | $-1.15B | $-349.2M | $-680.4M | $-391.3M | $-387.5M |
| Net Change in Cash | $649.2M | $417.1M | $140.0M | $-34.2M | $296.6M | $113.2M | $-675.9M | $657.1M |
| Free Cash Flow | $1.01B | $1.29B | $348.6M | $1.14B | $927.4M | $778.2M | $492.0M | $1.30B |